Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of the International AIDS Society
Published in: Journal of the International AIDS Society 1/2011

Open Access 01-12-2011 | Research

High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia

Authors: Laurent Ferradini, Vara Ouk, Olivier Segeral, Janin Nouhin, Anne Dulioust, Chanroeurn Hak, Isabelle Fournier, Nathalie Lerolle, Sopheak Ngin, Chhi Vun Mean, Jean-François Delfraissy, Eric Nerrienet

Published in: Journal of the International AIDS Society | Issue 1/2011

Login to get access

Abstract

Background

The number of patients on second-line highly active antiretroviral therapy (HAART) regimens is increasing in resource-limited settings. We describe the outcomes after 24 months for patients on LPV/r-based second-line regimens followed up by the ESTHER programme in Phnom Penh, Cambodia.

Methods

Seventy patients who initiated second-line HAART regimens more than 24 months earlier were included, and immuno-virological data analyzed. HIV RNA viral load was determined by real-time RT-PCR. HIV-1 drug resistance was interpreted according to the ANRS algorithm.

Results

Of the 70 patients, two were lost to follow up, three died and 65 (92.8%) remained on second-line treatment after 24 months of follow up (median duration of treatment: 27.4 months). At switch to second-line, the median CD4 T cell count was 106 cells/mm3 and the median viral load was 4.7 Log10. Second-line regimens prescribed were ddI/3TC/LPV/r (65.7%), ddI/TDF/LPV/r (10.0%), ddI/AZT/LPV/r (8.6%) and TDF/3TC/LPV/r (7.1%). The median CD4 T cell gain was +258 cells/mm3 at 24 months (n = 63). After 24 months of follow up, 92.3% (60/65) of the patients presented undetectable viral loads, giving an overall treatment success rate of 85.7% (CI: 75.6- 92.0) in intent-to-treat analysis.

Conclusions

These data suggest that a LPV/r-based second-line regimen is associated with a high rate of virological suppression and immune reconstitution after 24 months of follow up in Cambodia.
Literature
1.
Laurent C, Diakhaté N, Gueye NF, Touré MA, Sow PS, Faye MA, Gueye M, Lanièce I, Touré Kane C, Liégeois F, Vergne L, Mboup S, Badiane S, Ndoye I, Delaporte E: The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study. AIDS 2002, 16:1363–1370.PubMedCrossRef
2.
Laurent C, Kouanfack C, Koulla-Shiro S, Nkoué N, Bourgeois A, Calmy A, Lactuock B, Nzeusseu V, Mougnutou R, Peytavin G, Liégeois F, Nerrienet E, Tardy M, Peeters M, Andrieux-Meyer I, Zekeng L, Kazatchkine M, Mpoudi-Ngolé E, Delaporte E: Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet 2004, 364:29–34.PubMedCrossRef
3.
Orrell C, Bangsberg DR, Badri M, Wood R: Adherence is not a barrier to successful antiretroviral therapy in South Africa. AIDS 2003, 17:1369–1375.PubMedCrossRef
4.
Ferradini L, Jeannin A, Pinoges L, Izopet J, Odhiambo D, Mankhambo L, Karungi G, Szumilin E, Balandine S, Fedida G, Carrieri MP, Spire B, Ford N, Tassie JM, Guerin PJ, Brasher C: Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet 2006, 367:1335–1342.PubMedCrossRef
5.
Kumarasamy N, Solomon S, Chaguturu SK, Mahajan AP, Flanigan TP, Balakrishnan P, Mayer KH: The safety, tolerability and effectiveness of generic antiretroviral drug regimens for HIV-infected patients in south India. AIDS 2003, 17:2267–2269.PubMedCrossRef
6.
Weidle PJ, Malamba S, Mwebaze R, Sozi C, Rukundo G, Downing R, Hanson D, Ochola D, Mugyenyi P, Mermin J, Samb B, Lackritz E: Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. Lancet 2002, 360:34–40.PubMedCrossRef
7.
Coetzee D, Hildebrand K, Boulle A, Maartens G, Louis F, Labatala V, Reuter H, Ntwana N, Goemaere E: Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 2004, 18:887–895.PubMedCrossRef
8.
Madec Y, Laureillard D, Pinoges L, Fernandez M, Prak N, Ngeth C, Moeung S, Song S, Balkan S, Ferradini L, Quillet C, Fontanet A: Response to highly active antiretroviral therapy among severely immuno-compromised HIV-infected patients in Cambodia. AIDS 2007, 21:351–359.PubMedCrossRef
9.
Dabis F, Balestre E, Braitstein P, Miotti P, Brinkhof WG, Schneider M, Schechter M, Laurent C, Boulle A, Kabugo C, Capkun G, Seyler C, McIntyre J, Sprinz E, Bangsberg D, Van der Borght S, Egger M, Antiviral Therapy in Lower Income Countries (ART-LINC) Study Group: Cohort Profile: Antiretroviral Therapy in Lower Income Countries (ART-LINC): international collaboration of treatment cohorts. Int J Epidemiol 2005, 34:979–986.PubMedCrossRef
10.
Ivers LC, Kendrick D, Doucette K: Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clin Infect Dis 2005, 41:217–224.PubMedCrossRef
11.
World Health Organization: Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach. 2003 revision. WHO, Geneva;
12.
World Health Organization: Treating 3 million by 2005: making it happen. The WHO strategy. WHO, Geneva; 2003.
13.
World Health Organization, UNAIDS: Progress on global access to HIV antiretroviraltherapy: a report on "3 by 5" and beyond. WHO, Geneva; 2006.
14.
Gilks CF, Crowley S, Ekpini R, Gove S, Perriens J, Souteyrand Y, Sutherland D, Vitoria M, Guerma T, De Cock K: The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 2006, 368:505–510.PubMedCrossRef
15.
Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W: Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis 2007, 44:447–452.PubMedCrossRef
16.
Gallant JE: Drug resistance after failure of initial antiretroviral therapy in resource-limited countries. Clin Infect Dis 2007, 44:453–455.PubMedCrossRef
17.
World Health Organization: Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings: towards universal access. revision. Geneva; 2006.
18.
World Health Organization: Rapid Advice: Antiretroviral therapy for HIV infection in adults and adolescents. Geneva; 2009.
19.
Boyd MA, Cooper DA: Second-line combination antiretroviral therapy in resource-limited settings: facing the challenges through clinical research. AIDS 2007,21(Suppl 4):S55–63.PubMedCrossRef
20.
Pujades-Rodríguez M, O'Brien D, Humblet P, Calmy A: Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières. AIDS 2008, 22:1305–1312.PubMedCrossRef
21.
Ferradini Laurent: Efficacy of Kaletra-based Second Line Antiretroviral Treatment in Cambodia (K-1003). Presented at CROI conference: 25–28 February 2007. Los Angeles, USA;
22.
Fox MP, Ive P, Long L, Maskew M, Sanne I: High Rates of Survival, Immune Reconstitution and Virologic Suppression on Second-Line Antiretroviral Therapy in South Africa. J Acquir Immune Defic Syndr 2010, 53:500–506.PubMedCrossRef
23.
Castelnuovo B, John L, Lutwama F, Ronald A, Spacek LA, Bates M, Kamya MR, Colebunders R: Three-year outcome data of second-line antiretroviral therapy in Ugandan adults: good virological response but high rate of toxicity. J Int Assoc Physicians AIDS Care 2009, 8:52–59.CrossRef
24.
Pujades-Rodríguez M, Balkan S, Arnould L, Brinkof MAW, Calmy A: Treatment Failure and Mortality Factors in Patients Receiving Second-Line HIV Therapy in Resource-Limited Countries. JAMA 2010, 304:303–312.PubMedCrossRef
25.
UNAIDS: 2004 report on the global AIDS epidemic. Bangkok; 2004.
26.
NCHADS: Report on HIV sentinel surveillance in Cambodia. Phnom Penh; 2006.
27.
28.
Ségéral O, Limsreng S, Nouhin J, Hak CR, Ngin S, De Lavaissière M, Goujard C, Taburet AM, Nerrienet E, Delfraissy JF, Ouk V, Dulioust A: Three Years Follow-Up of First-Line Antiretroviral Therapy in Cambodia: Negative Impact of Prior Antiretroviral Treatment. AIDS Res Hum Retroviruses 2011.,27(00):
29.
Segeral O, Madec Y, Ban B, Ouk V, Hak CR, Le Tiec C, Nerrienet E, Goujard C, Taburet AM, Delfraissy JF, Fontanet A: Simplified Assessment of Antiretroviral Adherence and Prediction of Virological Efficacy in HIV-Infected Patients in Cambodia. AIDS Research and Treatment 2010, 2010:142076.PubMedCrossRef
30.
Rouet F, Ekouevi DK, Chaix ML, Burgard M, Inwoley A, Tony TD, Danel C, Anglaret X, Leroy V, Msellati P, Dabis F, Rouzioux C: Transfer and evaluation of an automated, low-cost real-time reverse transcription-PCR test for diagnosis and monitoring of human immunodeficiency virus type 1 infection in a West African resource-limited setting. J Clin Microbiol 2005, 43:2709–2717.PubMedCrossRef
31.
Rouet F, Chaix ML, Nerrienet E, Ngo-Giang-Huong N, Plantier JC, Burgard M, Peeters M, Damond F, Ekouevi DK, Msellati P, Ferradini L, Rukobo S, Maréchal V, Schvachsa N, Wakrim L, Rafalimanana C, Rakotoambinina B, Viard JP, Seigneurin JM, Rouzioux C: Impact of HIV-1 genetic diversity on plasma HIV-1 RNA quantification: usefulness of the ANRS second-generation LTR-based real-time RT-PCR. J Acquir Immune Defic Syndr 2007, 45:380–388.PubMedCrossRef
32.
Lan NT, Recordon-Pinson P, Hung PV, Uyen NT, Lien TT, Tien HT, Garrigue I, Schrive MH, Pellegrin I, Lafon ME, Aboulker JP, Barré-Sinousi F, Fleury HJ: HIV type 1 isolates from 200 untreated individuals in Ho Chi Minh City (Vietnam): ANRS 1257 Study. Large predominance of CRF01_AE and presence of major resistance mutations to antiretroviral drugs. AIDS Res Hum Retroviruses 2003, 19:925–928.PubMedCrossRef
33.
34.
Wei X, Liang C, Götte M, Wainberg MA: The M184V mutation in HIV-1 reverse transcriptase reduces the restoration of wild-type replication by attenuated viruses. AIDS 2002, 16:2391–2398.PubMedCrossRef
35.
Wainberg MA, Drosopoulos WC, Salomon H, Hsu M, Borkow G, Parniak M, Gu Z, Song Q, Manne J, Islam S, Castriota G, Prasad VR: Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Science 1996, 271:1282–1285.PubMedCrossRef
36.
Quan Y, Brenner BG, Oliveira M, Wainberg MA: Lamivudine can exert a modest antiviral effect against human immunodeficiency virus type 1 containing the M184V mutation. Antimicrob Agents Chemother 2003, 47:747–754.PubMedCrossRef
37.
Eron JJ Jr, Bartlett JA, Santana JL, Bellos NC, Johnson J, Keller A, Kuritzkes DR, St Clair MH, Johnson VA: Persistent antiretroviral activity of nucleoside analogues after prolonged zidovudine and lamivudine therapy as demonstrated by rapid loss of activity after discontinuation. J Acquir Immune Defic Syndr 2004, 37:1581–1583.PubMedCrossRef
38.
Castagna A, Danise A, Menzo S, Galli L, Gianotti N, Carini E, Boeri E, Galli A, Cernuschi M, Hasson H, Clementi M, Lazzarin A: Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study). AIDS 2006, 20:795–803.PubMedCrossRef
39.
Siripassorn K, Manosuthi W, Chottanapund S, Pakdee A, Sabaitae S, Prasithsirikul W, Tunthanathip P, Ruxrungtham K, Bamrasnaradura Study Team: Effectiveness of boosted protease inhibitor-based regimens in HIV type 1-infected patients who experienced virological failure with NNRTI-based antiretroviral therapy in a resource-limited setting. AIDS Res Hum Retroviruses 2010,26(2):139–148.PubMedCrossRef
Metadata
Title
High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia
Authors
Laurent Ferradini
Vara Ouk
Olivier Segeral
Janin Nouhin
Anne Dulioust
Chanroeurn Hak
Isabelle Fournier
Nathalie Lerolle
Sopheak Ngin
Chhi Vun Mean
Jean-François Delfraissy
Eric Nerrienet
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Journal of the International AIDS Society / Issue 1/2011
Electronic ISSN: 1758-2652
DOI
https://doi.org/10.1186/1758-2652-14-14

Other articles of this Issue 1/2011

Journal of the International AIDS Society 1/2011 Go to the issue

Research

A cross-sectional assessment of population demographics, HIV risks and human rights contexts among men who have sex with men in Lesotho

Review

Male circumcision for HIV prevention: current evidence and implementation in sub-Saharan Africa

Research

"Othering" the health worker: self-stigmatization of HIV/AIDS care among health workers in Swaziland

Research

Towards targeted screening for acute HIV infections in British Columbia

Research

Uptake of prevention of mother to child transmission interventions in Kenya: health systems are more influential than stigma

Research

The Global Fund's resource allocation decisions for HIV programmes: addressing those in need
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits